Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kullberg

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Pharmaceutics|April 26, 2025
C3-Liposome Delivery of MUC1 Peptide and TLR Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth DifferencesShahab Soltani, Ameneh Arabi, Kristine Mann, et al.
Pharmaceutics|December 23, 2023
Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-LiposomesAmeneh Arabi, Shahab Aria Soltani, Brandon Maniaci, et al.
International Journal of Molecular Sciences|June 13, 2025
Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune ResponseR G Barber, Steven Cherry, Sydney Stephens, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 20, 2014
Biodistribution and delivery efficiency of unmodified tumor-derived exosomesTyson Smyth, Max Kullberg, Noeen Malik, et al.
Journal of Drug Targeting|January 21, 2021
Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growthAlexandra Francian, Ashley Widmer, Troy Olsson, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Pharmaceutics|April 26, 2025
C3-Liposome Delivery of MUC1 Peptide and TLR Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth DifferencesShahab Soltani, Ameneh Arabi, Kristine Mann, et al.
Pharmaceutics|December 23, 2023
Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-LiposomesAmeneh Arabi, Shahab Aria Soltani, Brandon Maniaci, et al.
International Journal of Molecular Sciences|June 13, 2025
Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune ResponseR G Barber, Steven Cherry, Sydney Stephens, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 20, 2014
Biodistribution and delivery efficiency of unmodified tumor-derived exosomesTyson Smyth, Max Kullberg, Noeen Malik, et al.
Journal of Drug Targeting|January 21, 2021
Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growthAlexandra Francian, Ashley Widmer, Troy Olsson, et al.
Pageof 2